Thus far, the company has paid about 1 percent of its revenue ($75 million out of $7.4 billion) under the medical device tax. Due to the tax reprieve, Boston Scientific is now putting that money toward research.
Currently, implanted stents are sometimes forgotten or left in for too long - 13 out of 100 according to the company.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Venture capital went up quite a bit in 2015 reaching $59 billion, more than doubling in the last five years - but according to the latest Silicon Valley Bank report, only $2.4 billion went into medical devices.
Boston Scientific (BSX) received FDA device approval for its Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, a next-gen polymer drug-eluting stent. The product launches immediately in the U.S. It will be used to treat patients with coronary artery disease. The company boasts the system offers “unparalleled visibility, low recoil, exceptional radial strength and fracture resistance, […]
Boston Scientific (BSX) has taken its new investor relations VP from Abiomed (ABMD), the company known for the world’s smallest heart pump and AbioCor. Susan Lisa has served as the senior director of investor relations and corporate development at Abiomed since 2012, according to her LinkedIn profile. She will begin her role as VP of […]
Boston Scientific (BSX) received FDA clearance and the CE Mark for its Direxion Torqueable Microcatheter. The catheter is the company’s newest addition to its peripheral embolization medical device technology portfolio. Radiologists use peripheral embolization to treat liver cancer and uterine fibroids, among other conditions. “It involves deliberately blocking a blood vessel to prevent blood flow to […]
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Boston Scientific (BSX) announced it has received the CE Mark for its Vercise Deep Brain Stimulation System for the treatment of dystonia, “a neurological movement disorder characterized by involuntary muscle contractions.” Dystonia is the third most common movement disorder after Parkinson’s disease and essential tremor, and more than 500,000 patients in Europe have it, according […]
The Supreme Court heard oral arguments in Medtronic (MDT) vs. Boston Scientific (BSX) in a patent litigation lawsuit Tuesday. Chances are the Minnesota-based medical device company will win this one. Luckily for Boston Scientific, logic doesn’t always play into legal interpretation. In 1991, Boston Scientific made a licensing agreement with Medtronic for its CRT medical […]
Healthcare business intelligence: Boston Scientific (BSX) closed on its acquisition of C.R. Bard‘s Bard EP Nov. 1. According to a company statement, the addition of Bard’s advanced therapeutic catheters, diagnostic catheters, electrophysiology recording systems and intracardiac access devices will help BSX address the $2.5 billion EP market, which is growing by as much as 10 percent yearly. […]
Two top medical device companies turned up the heat on the renal denervation competition. Both Boston Scientific (BSX) and St. Jude Medical (STJ) delivered promising results from studies on their two respective renal denervation technologies at the Transcatheter Cardiovascular Therapeutics conference in San Francisco. Such technology uses radiofrequency ablation on the nerves leading to the […]
Executives from Imagine360, Verily, BrightInsight, Lantern, and Rhapsody shared their approaches to reducing healthcare costs and facilitating digital transformation.
Boston Scientific (BSX) announced the medical device company has received a CE Mark for its Lotus Valve System, which offers alternative treatment for high-risk patients with sever aortic stenosis. The advanced transcatheter aortic valve replacement (TAVR) technology, the company claims, is “the only aortic valve device that can be assessed in its final position prior […]
A changing of the guard: Dan Brennan will become Boston Scientific‘s (BSX) new CFO effective Jan. 1. Company CFO Jeffrey Capello will stay with the company through May to help as a senior advisor and probably to help Brennan transition into the role. His reason for leaving is still vague. A company statement said he […]
Guidant continues to prove itself as Boston Scientific’s biggest legal headache. Reuters reports Boston Scientific (BSX) has agreed to pay a $30 million settlement to bring two-year civil lawsuit, and with it allegations that Guidant knowingly sold defective defibrillators used in Medicare patients, to an end. BSX bought Guidant in 2006. Guidant sold the defibrillators, which […]
Neuros Medical, a Cleveland-based medical device company, received an FDA investigational device exemption approval to begin a clinical study on its technology for intractable limb pain management for amputees. According to the company website, the Altius System High Frequency Nerve Block technology “consists of an electrode (also known as a lead) placed around a peripheral […]
Materna Medical is at work on a device to help protect the more than 80 percent of women who suffer damage or tearing during childbirth. “The clinical need we’re trying to address is that there’s a tremendous amount of damage that women suffer during childbirth,” Mark Juravic, founder and CEO of the California-based startup, said. That […]